Key points are not available for this paper at this time.
presence of nonprofit manufacturers will bring increased competition to areas of the generic-drug market where market failure is prevalent, which will motivate for-profit manufacturers to reduce prices and stabilize supply.
Justman et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: